HIVconsv

**HIVconsv** is a therapeutic vaccine immunogen designed to elicit cytotoxic T-lymphocyte (CTL) responses against highly conserved regions of the HIV-1 proteome. It comprises a chimeric protein assembled from 14 conserved domains from HIV-1 genes **Gag**, **Pol**, **Vif**, and **Env**, using consensus sequences from the four major clades (A, B, C, D). Delivered via viral vectors such as chimpanzee adenovirus (ChAdV63.HIVconsv) for priming and modified vaccinia Ankara (MVA.HIVconsv) for boosting, it induces broad, focused CD8+ T-cell responses capable of inhibiting HIV-1 replication *in vitro*. Developed by the **University of Oxford**, it has been tested in phase I/II trials, including **BCN01** and **BCN02**, primarily in early-treated HIV-1-infected individuals on antiretroviral therapy (ART), often combined with latency-reversing agents like romidepsin in "kick-and-kill" strategies to target the latent viral reservoir.[1][2][11]